DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Wolf-Hirschhorn syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleWolf-Hirschhorn syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for wolf-hirschhorn syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Wolf-Hirschhorn syndrome is caused by deletions on the short arm of chromosome 4, and the precise size and location of the deletion determine whether a person develops the full syndrome or only some features. A 2008 review notes that individuals with microdeletions distal to the currently described critical regions on 4p16.3 sometimes do not display features consistent with Wolf-Hirschhorn syndrome, while others have a phenotype that partially overlaps it. The review attempts to identify the distal boundary for pathogenic genes involved in components of the syndrome.
A 2019 report on an international meeting held in Madrid in 2017 describes 125 attendees including physicians, scientists, and affected families. The meeting followed a progression from describing the phenotype and defining therapeutic endpoints to defining genomic changes, with the stated theme of therapeutic development. No therapeutic results are reported.
A 2021 study of ten Egyptian patients confirmed the diagnosis by karyotype, FISH, MLPA, and array CGH, and reports a new clinical finding that extends the phenotypic spectrum of the disorder. A 2016 case report used single nucleotide polymorphism array to identify a 13.3 Mb hemizygous deletion on chromosome 4p16.3p15.33 in a child with multiple congenital malformations and epilepsy, confirming a de novo origin. The authors state that SNP-array has greater resolution and accuracy than conventional karyotyping.
No clinical trial data, no survival statistics, no response rates, and no treatment outcomes are reported in any of these abstracts. What is missing is any funded trial of a specific intervention, a defined patient stratification strategy based on deletion size, and a set of validated clinical endpoints that could be used to measure benefit in this rare and heterogeneous disorder.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part C Seminars in Medical Genetics · 2008 · 45 citations
Pathogenic significance of deletions distal to the currently described Wolf–Hirschhorn syndrome critical regions on 4p16.3
AbstractWithin recent years, numerous individuals have been identified with terminal 4p microdeletions distal to the currently described critical regions for the Wolf-Hirschhorn syndrome (WHS). Some of these individuals do not display features consistent with WHS whereas others have a clinical phenotype with some overlap to the WHS phenotype. In this review we discuss the genetic and clinical presentation of these cases in an attempt to understand the consequence of monosomy of the genes distal to the proposed critical regions and identify the distal boundary for pathogenic genes involved in components of the WHS phenotype.
American Journal of Medical Genetics Part A · 2019 · 28 citations
International meeting on Wolf‐Hirschhorn syndrome: Update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay
Abstract"An International Meeting on Wolf-Hirschhorn Syndrome (WHS)" was held at The University Hospital La Paz in Madrid, Spain (October 13-14, 2017). One hundred and twenty-five people, including physicians, scientists and affected families, attended the meeting. Parent and patient advocates from the Spanish Association of WHS opened the meeting with a panel discussion to set the stage regarding their hopes and expectations for therapeutic advances. In keeping with the theme on therapeutic development, the sessions followed a progression from description of the phenotype and definition of therapeutic endpoints, to definition of genomic changes. These proceedings will review the major points of discussion.
Molecular Genetics & Genomic Medicine · 2021 · 0 citations · open access
Abstractclinical, neurological, and molecular cytogenetic analysis of 10 Egyptian patients diagnosed with Wolf–Hirschhorn syndrome (WHS). Diagnosis was confirmed by genetic analysis through karyotype, FISH, MLPA, and array CGH with a new clinical finding which that, to our knowledge, was not reported before in WHS, extending the phenotypic spectrum of the disorder.
[A case of Wolf-Hirschhorn syndrome diagnosed by single nucleotide polymorphism array].
AbstractOBJECTIVE: To explore the genetic causes for a child with multiple congenital malformations and epilepsy through analysis of copy number variations, and to correlate the genotype with the phenotype. METHODS: G-banding karyotyping was performed on the child and her parents. Single nucleotide polymorphisms array (SNP-array) was used to map the exact chromosomal breakpoints in the proband. The result was validated with fluorescence in situ hybridization (FISH). RESULTS: G banding analysis suggested that the proband had a karyotype of 46,XX,del(4)(p15), while both of his parents had a normal karyotype. SNP-array has identified a hemizygous deletion of 13.3 Mb on chromosome 4p16.3p15.33, which has been implicated in Wolf-Hirschhorn syndrome. FISH assay has confirmed the de novo origin of the deletion, with the karyotype and clinical phenotype of both parents taken into consideration. CONCLUSION: A case of Wolf-Hirschhorn syndrome has been diagnosed by clinical manifestation and karyotyping analysis. Compared with conventional karyotyping analysis, SNP-array has greater resolution and accuracy, and can provide useful information for genetic counseling.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
